Acceleration of Allograft Failure by Cytomegalovirus

Overview

Journal Curr Opin Immunol

Publisher Elsevier

Specialty Allergy & Immunology

Date 2007 Aug 25

PMID 17716883

Citations 51

Authors

Daniel N Streblow

Susan L Orloff

Jay A Nelson

Affiliations

Soon will be listed here.

Abstract

A number of human herpesviruses are important opportunistic pathogens that have been associated with increased morbidity and mortality in transplant recipients including human cytomegalovirus (HCMV), HHV6, HHV7, HHV8 as well as HSV-1, VZV. However, HCMV has been linked both epidemiologically and through the use of animal models to the acceleration of acute and chronic allograft rejection. This review will cover the pathophysiology, epidemiology, and mechanisms of CMV-associated disease in the setting of transplantation.

Citing Articles

Cytomegalovirus immunity in high-risk liver transplant recipients following preemptive antiviral therapy versus prophylaxis.

Zamora D, Dasgupta S, Stevens-Ayers T, Edmison B, Winston D, Razonable R JCI Insight. 2024; 9(18).

PMID: 39099206 PMC: 11457861. DOI: 10.1172/jci.insight.180115.

Human cytomegalovirus infection triggers a paracrine senescence loop in renal epithelial cells.

Raviola S, Griffante G, Iannucci A, Chandel S, Lo Cigno I, Lacarbonara D Commun Biol. 2024; 7(1):292.

PMID: 38459109 PMC: 10924099. DOI: 10.1038/s42003-024-05957-5.

Human cytomegalovirus and Epstein-Barr virus infections occurring early after transplantation are risk factors for antibody-mediated rejection in heart transplant recipients.

Saldan A, Mengoli C, Sgarabotto D, Fedrigo M, Angelini A, Feltrin G Front Immunol. 2023; 14:1171197.

PMID: 37256129 PMC: 10225529. DOI: 10.3389/fimmu.2023.1171197.

Don't Go Breaking My Heart: MCMV as a Model for HCMV-Associated Cardiovascular Diseases.

Bonavita C, Cardin R Pathogens. 2021; 10(5).

PMID: 34069957 PMC: 8157551. DOI: 10.3390/pathogens10050619.

Update in Viral Infections in the Intensive Care Unit.

Fragkou P, Moschopoulos C, Karofylakis E, Kelesidis T, Tsiodras S Front Med (Lausanne). 2021; 8:575580.

PMID: 33708775 PMC: 7940368. DOI: 10.3389/fmed.2021.575580.

References

Shahgasempour S, Woodroffe S, Garnett H . Alterations in the expression of ELAM-1, ICAM-1 and VCAM-1 after in vitro infection of endothelial cells with a clinical isolate of human cytomegalovirus. Microbiol Immunol. 1997; 41(2):121-9. DOI: 10.1111/j.1348-0421.1997.tb01177.x. View

Vieira J, Schall T, Corey L, Geballe A . Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene. J Virol. 1998; 72(10):8158-65. PMC: 110158. DOI: 10.1128/JVI.72.10.8158-8165.1998. View

Humar A, St Louis P, Mazzulli T, McGeer A, Lipton J, Messner H . Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients. J Infect Dis. 1999; 179(2):484-8. DOI: 10.1086/314602. View

Burns L, Pooley J, Walsh D, Vercellotti G, Weber M, Kovacs A . Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins. Transplantation. 1999; 67(1):137-44. DOI: 10.1097/00007890-199901150-00023. View

Zhou Y, Yu Z, Wanishsawad C, Shou M, Epstein S . The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta-receptor. Biochem Biophys Res Commun. 1999; 256(3):608-13. DOI: 10.1006/bbrc.1999.0387. View

Valantine H, Gao S, Menon S, Renlund D, Hunt S, Oyer P . Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation. 1999; 100(1):61-6. DOI: 10.1161/01.cir.100.1.61. View

Reinhardt B, Schaarschmidt P, Bossert A, Luske A, Finkenzeller G, Mertens T . Upregulation of functionally active vascular endothelial growth factor by human cytomegalovirus. J Gen Virol. 2004; 86(Pt 1):23-30. DOI: 10.1099/vir.0.80327-0. View

Sparer T, Gosling J, Schall T, Mocarski E . Expression of human CXCR2 in murine neutrophils as a model for assessing cytomegalovirus chemokine vCXCL-1 function in vivo. J Interferon Cytokine Res. 2005; 24(10):611-20. DOI: 10.1089/jir.2004.24.611. View

Streblow D, Kreklywich C, Smith P, Soule J, Meyer C, Yin M . Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. Am J Transplant. 2005; 5(3):436-42. DOI: 10.1111/j.1600-6143.2004.00711.x. View

10.

Streblow D, Soderberg-Naucler C, Vieira J, Smith P, Wakabayashi E, Ruchti F . The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell. 1999; 99(5):511-20. DOI: 10.1016/s0092-8674(00)81539-1. View

11.

Srivastava R, Curtis M, Hendrickson S, BURNS W, Hosenpud J . Strain specific effects of cytomegalovirus on endothelial cells: implications for investigating the relationship between CMV and cardiac allograft vasculopathy. Transplantation. 1999; 68(10):1568-73. DOI: 10.1097/00007890-199911270-00022. View

12.

Schaarschmidt P, Reinhardt B, Michel D, Vaida B, Mayr K, Luske A . Altered expression of extracellular matrix in human-cytomegalovirus-infected cells and a human artery organ culture model to study its biological relevance. Intervirology. 2000; 42(5-6):357-64. DOI: 10.1159/000053972. View

13.

Orloff S, Yin Q, Corless C, Orloff M, Rabkin J, Wagner C . Tolerance induced by bone marrow chimerism prevents transplant vascular sclerosis in a rat model of small bowel transplant chronic rejection. Transplantation. 2000; 69(7):1295-303. DOI: 10.1097/00007890-200004150-00015. View

14.

Ljungman P, Deliliers G, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H . Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2001; 97(2):388-92. DOI: 10.1182/blood.v97.2.388. View

15.

Hart G, Paya C . Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol. 2001; 11(2):73-81. DOI: 10.1002/rmv.309. View

16.

Emery V . Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol. 2001; 11(2):83-6. DOI: 10.1002/rmv.310. View

17.

Tikkanen J, Kallio E, Pulkkinen V, Bruggeman C, Koskinen P, Lemstrom K . Cytomegalovirus infection-enhanced chronic rejection in the rat is prevented by antiviral prophylaxis. Transplant Proc. 2001; 33(1-2):1801. DOI: 10.1016/s0041-1345(00)02686-5. View

18.

Rott D, Zhu J, Burnett M, Zhou Y, Wasserman A, Walker J . Serum of cytomegalovirus-infected mice induces monocyte chemoattractant protein-1 expression by endothelial cells. J Infect Dis. 2001; 184(9):1109-13. DOI: 10.1086/323745. View

19.

Nichols W, Corey L, Gooley T, Davis C, Boeckh M . High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002; 185(3):273-82. DOI: 10.1086/338624. View

20.

Song Y, Stinski M . Effect of the human cytomegalovirus IE86 protein on expression of E2F-responsive genes: a DNA microarray analysis. Proc Natl Acad Sci U S A. 2002; 99(5):2836-41. PMC: 122434. DOI: 10.1073/pnas.052010099. View